A Second Malaria Vaccine Is Approved by WHO

A second malaria vaccine was approved by the World Health Organization (WHO) last week. The choice might provide an easily available, less expensive vaccine to aid in the fight against the illness. According to Tedros Adhanom Ghebreyesus, director-general of WHO, the new malaria vaccine was authorized by the U.N. health agency on the recommendation of two expert panels. They proposed that kids who are susceptible to the illness could receive the vaccination. As a researcher on malaria, I used to look forward to the day when a secure and reliable vaccine against the disease would be available. We now have two,” Tedros remarked.


The new three-shot vaccination was developed by Oxford University in Britain and the Serum Institute of India. Studies indicate that its efficacy exceeds 75%. With a follow-up injection known as a booster, the vaccination can shield recipients for an extra year. Tedros estimated that the shot would run between $2 and $4 and be accessible in a few nations by the following year. The vaccine was also approved earlier this year by health authorities in Ghana and Burkina Faso, two African nations.


According to John Johnson of Doctors Without Borders, “this is one more tool we will have, but it’s not going to replace bed nets and spraying insecticides.” He went on, “This vaccine is not going to stop malaria.” Johnson was excluded from the expert panels that provided the WHO with advice. In 2021, the WHO authorized the first malaria vaccination. The creation of the vaccine, according to the U.N. agency, represents a “historic” attempt to eradicate the fatal illness in Africa. The majority of the 200 million malaria cases and 400,000 malaria fatalities worldwide are thought to occur on the continent.


WHO specialists, however, stated that the available evidence on the vaccines created by GSK and Oxford does not indicate which is more effective. One of the main financial backers of the GSK vaccination was the Bill & Melinda Gates Foundation. However, the nonprofit stopped endorsing Mosquirix a year ago. It said that money would be better spent elsewhere and that the GSK shot was less effective than officials would have liked. Access is the main distinction between these two vaccinations, Johnson told the Associated Press. He mentioned that in the coming years, the GSK vaccine might be available in at least ten nations.

Be the first to comment

Leave a Reply

Your email address will not be published.